Verona Pharma PLC American Depositary Share (NASDAQ:VRNA) Director Sells $124,356.96 in Stock

Key Points

• Lisa Deschamps, a director at Verona Pharma, sold 9,464 shares for approximately $124,357, decreasing her ownership by 10.03% to 84,856 shares.
• The company's stock price recently traded down 0.1% to $105.40, with a market capitalization of $8.97 billion.
• Multiple analysts have downgraded Verona Pharma's stock, bringing the consensus rating to "Hold" with a target price of $109.00.

Verona Pharma PLC American Depositary Share (NASDAQ:VRNA - Get Free Report) Director Lisa Deschamps sold 9,464 shares of the business's stock in a transaction that occurred on Friday, August 1st. The shares were sold at an average price of $13.14, for a total transaction of $124,356.96. Following the completion of the transaction, the director directly owned 84,856 shares of the company's stock, valued at approximately $1,115,007.84. This represents a 10.03% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.

Verona Pharma PLC American Depositary Share Trading Down 0.1%

VRNA stock traded down $0.07 during midday trading on Tuesday, reaching $105.40. 861,362 shares of the company's stock traded hands, compared to its average volume of 8,219,019. The company has a market capitalization of $8.97 billion, a P/E ratio of -52.70 and a beta of 0.12. The company has a debt-to-equity ratio of 1.07, a current ratio of 8.86 and a quick ratio of 8.73. Verona Pharma PLC American Depositary Share has a fifty-two week low of $19.45 and a fifty-two week high of $105.50. The business has a 50-day moving average price of $94.93 and a two-hundred day moving average price of $74.38.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in VRNA. NBC Securities Inc. acquired a new position in shares of Verona Pharma PLC American Depositary Share during the first quarter worth $34,000. Geneos Wealth Management Inc. lifted its position in shares of Verona Pharma PLC American Depositary Share by 44.2% during the first quarter. Geneos Wealth Management Inc. now owns 630 shares of the company's stock worth $40,000 after purchasing an additional 193 shares in the last quarter. Vermillion Wealth Management Inc. acquired a new position in shares of Verona Pharma PLC American Depositary Share during the fourth quarter worth $46,000. Acadian Asset Management LLC acquired a new position in shares of Verona Pharma PLC American Depositary Share during the first quarter worth $48,000. Finally, IFP Advisors Inc acquired a new position in shares of Verona Pharma PLC American Depositary Share during the second quarter worth $52,000. 85.88% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of research firms have recently weighed in on VRNA. Cowen lowered shares of Verona Pharma PLC American Depositary Share from a "buy" rating to a "hold" rating in a research report on Wednesday, July 9th. BTIG Research lowered shares of Verona Pharma PLC American Depositary Share from a "strong-buy" rating to a "hold" rating in a research report on Thursday, July 10th. Roth Capital lowered shares of Verona Pharma PLC American Depositary Share from a "strong-buy" rating to a "hold" rating in a research report on Thursday, July 10th. HC Wainwright restated a "neutral" rating and issued a $107.00 target price (up from $90.00) on shares of Verona Pharma PLC American Depositary Share in a report on Monday, July 14th. Finally, Wells Fargo & Company downgraded shares of Verona Pharma PLC American Depositary Share from a "strong-buy" rating to a "hold" rating and lowered their target price for the company from $138.00 to $107.00 in a report on Thursday, July 10th. Eleven analysts have rated the stock with a hold rating and two have given a buy rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Hold" and a consensus price target of $109.00.

About Verona Pharma PLC American Depositary Share

Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.